- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01224171
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease (GEMINI III)
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
After completing the study, patients were eligible to enroll in a long term safety study with continued access to vedolizumab (study C13008; NCT00790933) if study drug was well tolerated, and no major surgical intervention for Crohn's disease occurred or was required.
Participants who did not enroll in Study C13008 were to complete the Final Safety visit (16 weeks after the last dose of study drug) for a maximum time on study of 22 weeks.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G2X8
- Zeidler Ledcor Center-Univerisity of Alberta
-
-
-
-
Colorado
-
Lafayette, Colorado, Yhdysvallat, 80026
- Gastroenterology of the Rockies
-
-
Connecticut
-
Hamden, Connecticut, Yhdysvallat, 65180
- Gastroenterology Center of Connecticut P.C.
-
-
Florida
-
Gainesville, Florida, Yhdysvallat, 32610
- University of Florida
-
Miami, Florida, Yhdysvallat, 33136
- University of Miami Miller School of Medicine
-
Winter Park, Florida, Yhdysvallat, 32789
- Shafran Gastroenterology Center
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30342
- Atlanta Gastroenterology Associates
-
Macon, Georgia, Yhdysvallat, 31201
- Gastroenterology Associates of Central Georgia
-
Suwanee, Georgia, Yhdysvallat, 30024
- Atlanta Gastroenterology Specialist PC
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60637
- University of Chicago Medical Center
-
-
Kansas
-
Topeka, Kansas, Yhdysvallat, 66606
- Cotton O'Neil Digestive Health Center
-
-
Kentucky
-
Lexington, Kentucky, Yhdysvallat, 40536
- University of Kentucky Medical Center
-
Louisville, Kentucky, Yhdysvallat, 40402
- University of Louisville
-
-
Louisiana
-
Baton Rouge, Louisiana, Yhdysvallat, 70809
- Gastroenterology Associates
-
Hammond, Louisiana, Yhdysvallat, 70403
- Gastroenterology Research Of New Orleans
-
-
Maryland
-
Chevy Chase, Maryland, Yhdysvallat, 20815
- Metropolitan Gastroenterology Group P.C.
-
Hollywood, Maryland, Yhdysvallat, 20636
- Mid-Atlantic Medical Research Center
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02114
- Massachusetts General Hospital Crohn's and Colitis Center
-
-
Michigan
-
Ann Arbor, Michigan, Yhdysvallat, 48109
- University of Michigan
-
Troy, Michigan, Yhdysvallat, 48098
- Center for Digestive Health
-
Ypsilanti, Michigan, Yhdysvallat, 48197
- Huron Gastroenterology Associates
-
-
Minnesota
-
Plymouth, Minnesota, Yhdysvallat, 55446
- Minnesota Gastroenterology P.A.
-
Rochester, Minnesota, Yhdysvallat, 55905
- Mayo Clinic
-
-
Missouri
-
St. Louis, Missouri, Yhdysvallat, 63110
- Washington University
-
-
New Hampshire
-
Lebanon, New Hampshire, Yhdysvallat, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New York
-
Great Neck, New York, Yhdysvallat, 11021
- Long Island Clinical Research Associates
-
New York, New York, Yhdysvallat, 10021
- New York Presbyterian Hospital
-
Rochester, New York, Yhdysvallat, 14642
- University of Rochester
-
-
North Carolina
-
Chapel Hill, North Carolina, Yhdysvallat, 27599
- University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, Yhdysvallat, 28207
- Charlotte Gastroenterology and Hepatology P.L.L.C
-
-
Ohio
-
Cincinnati, Ohio, Yhdysvallat, 45219
- Consultants for Clinical Research Inc.
-
-
Oklahoma
-
Tulsa, Oklahoma, Yhdysvallat, 74104
- Options Health Research
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97225
- The Oregon Clinic-West Hills Gastroenterology
-
-
South Carolina
-
Columbia, South Carolina, Yhdysvallat, 29203
- Consultants in Gastroenterology
-
-
Tennessee
-
Germantown, Tennessee, Yhdysvallat, 38138
- Gastroenterology Center of the MidSouth PC
-
-
Texas
-
San Antonio, Texas, Yhdysvallat, 78229
- Gastroenterology Clinic of San Antonio
-
Tyler, Texas, Yhdysvallat, 75701
- Digestive Health Specialists of Tyler
-
-
Virginia
-
Charlottesville, Virginia, Yhdysvallat, 22908
- University of Virginia Health System
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98195
- University of Washington School of Medicine
-
-
Wisconsin
-
Milwaukee, Wisconsin, Yhdysvallat, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Yhdysvallat, 53215
- Wisconsin Center for Advanced Research
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age 18 to 80
- Diagnosis of moderately to severely active Crohn's disease
- Crohn's Disease involvement of the ileum and/or colon
- Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least one conventional therapy as defined by the protocol
- May be receiving a therapeutic dose of conventional therapies for inflammatory bowel disease (IBD) as defined by the protocol
Exclusion Criteria
- Evidence of abdominal abscess at the initial screening visit
- Extensive colonic resection, subtotal or total colectomy
- History of >3 small bowel resections or diagnosis of short bowel syndrome
- Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
- Have received non permitted therapies within either 30 or 60 days, depending on the medication, as stated in the protocol
- Chronic hepatitis B or C infection; human immunodeficiency virus (HIV) infection
- Active or latent tuberculosis
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Placebo Comparator: Placebo
Participants received placebo intravenous infusion at Weeks 0, 2 and 6.
|
Plasebo suonensisäinen infuusio
|
Kokeellinen: Vedolizumab
Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.
|
Vedolitsumabi suonensisäiseen infuusioon
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation
Aikaikkuna: Week 6
|
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:
The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission. |
Week 6
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Percentage of Participants in Clinical Remission at Week 6 in the Overall Population
Aikaikkuna: Week 6
|
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:
The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission. |
Week 6
|
Percentage of Participants in Clinical Remission at Week 10 in the TNFα Antagonist Failure Subpopulation
Aikaikkuna: Week 10
|
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:
The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission. |
Week 10
|
Percentage of Participants in Clinical Remission at Week 10 in the Overall Population
Aikaikkuna: Week 10
|
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:
The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission. |
Week 10
|
Percentage of Participants With Sustained Clinical Remission in the TNFα Antagonist Failure Population
Aikaikkuna: Week 6 and Week 10
|
Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:
The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission. |
Week 6 and Week 10
|
Percentage of Participants With Sustained Clinical Remission in the Overall Population
Aikaikkuna: Week 6 and Week 10
|
Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:
The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission. |
Week 6 and Week 10
|
Percentage of Participants With Enhanced Clinical Response at Week 6 in the TNFα Antagonist Failure Subpopulation
Aikaikkuna: Baseline and Week 6
|
Enhanced clinical response is defined as a ≥ 100-point decrease in CDAI score from Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:
The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response. |
Baseline and Week 6
|
Number of Participants With Adverse Events (AEs)
Aikaikkuna: From the date of first study drug administration to Week 22, through the 14 March 2012 database lock date. At the time of this database lock, 7 patients had completed Week 10 or early termination assessments but not Week 22 assessments.
|
An AE was defined as any untoward medical occurrence in a patient administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was any AE, occurring at any dose and regardless of causality that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event based upon appropriate medical judgment that may have jeopardized the patient and may have required medical or surgical intervention to prevent 1 of the outcomes listed above, or any diagnosis of progressive multifocal leukoencephalopathy (PML). Relationship to study drug administration was determined by the investigator responding yes or no to the question: Is there a reasonable possibility that the AE is associated with the study drug? |
From the date of first study drug administration to Week 22, through the 14 March 2012 database lock date. At the time of this database lock, 7 patients had completed Week 10 or early termination assessments but not Week 22 assessments.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019 Jul 17;25(8):1375-1382. doi: 10.1093/ibd/izy384.
- Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi: 10.1093/ecco-jcc/jjy125.
- Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7. doi: 10.1016/j.cgh.2018.05.026. Epub 2018 May 29. Erratum In: Clin Gastroenterol Hepatol. 2020 Mar;18(3):759.
- Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.
- Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul;42(2):188-202. doi: 10.1111/apt.13243. Epub 2015 May 20. Erratum In: Aliment Pharmacol Ther. 2015 Nov;42(9):1135.
- Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- C13011
- U1111-1158-2581 (Rekisterin tunniste: WHO)
- 2009-016488-12 (EudraCT-numero)
- NL34356.078.10 (Rekisterin tunniste: CCMO)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Plasebo
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyValmisMiespotilaat, joilla on tyypin II diabetes (T2DM)Saksa
-
National Institute on Drug Abuse (NIDA)ValmisKannabiksen käyttöYhdysvallat
-
Chiesi Farmaceutici S.p.A.ValmisAstmaYhdistynyt kuningaskunta
-
MedImmune LLCValmis
-
Eli Lilly and CompanyLopetettuNivelreumaYhdysvallat, Saksa, Taiwan, Ranska, Japani, Meksiko, Puola, Venäjän federaatio, Espanja, Kolumbia, Argentiina, Kreikka, Uusi Seelanti, Etelä-Afrikka, Australia, Korean tasavalta, Brasilia, Italia, Malesia
-
Alzheon Inc.National Institute on Aging (NIA)Aktiivinen, ei rekrytointiVarhainen Alzheimerin tautiYhdysvallat, Espanja, Kanada, Alankomaat, Tšekki, Yhdistynyt kuningaskunta, Ranska, Saksa, Islanti
-
GlaxoSmithKlineValmisLihavuus | Diabetes mellitus, tyyppi 2Yhdistynyt kuningaskunta
-
Chonbuk National University HospitalValmisToiminnallinen ummetusKorean tasavalta
-
Vitae Pharmaceuticals Inc., an Allergan affiliateValmis
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... ja muut yhteistyökumppanitValmisTerveYhdysvallat, Puerto Rico